Kowa Company, Ltd.
https://www.kowa.co.jp/eng/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kowa Company, Ltd.
Coronavirus Notebook: EU Invests In Convalescent Plasma, ACT-Accelerator Wants More Vaccines
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.
Coronavirus Update: BioNTech Gets €375m From Germany To Fund Vaccine
Plus: Valneva confirms supply deal with the UK government for its inactivated vaccine candidate; Humanigen expands manufacturing ahead of Phase III data.
Finance Watch: $320m In New VC Deals Includes $110m Round For Neogene
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
Israel VC Backs MiNA's Novel SaRNAs In Cancer, And Add-On Therapy Areas
Small activating RNA research being pioneered by London, UK-based MiNA Therapeutics has attracted $30m in a series A funding, led by a tech billionaire-backed life sciences VC fund.
Company Information
- Industry
- Diversified
-
Pharmaceuticals
- OTC, Consumer
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
- Other Names / Subsidiaries
-
- ProEthic Pharmaceuticals